Eisai's Kisplyx approved in EU for kidney cancer

The European Commission approved Kisplyx lenvatinib from Eisai Co. Ltd. (Tokyo:4523) in combination with Afinitor everolimus to treat advanced renal cell carcinoma (RCC) in patients previously treated with a VEGF inhibitor.

In May, FDA approved the inhibitor of multiple VEGF receptor tyrosine kinases for the same indication. The drug is marketed for thyroid cancer in the U.S. and EU, and is known as Lenvima in some countries. ...